½ÃÀ庸°í¼­
»óÇ°ÄÚµå
1375886

´ºÅ¬·¹¿ÀƼµå ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® ¸®Æ÷Æ® : Á¦Ç°º°, ±â¼úº°, ¿ëµµº°, Áö¿ªº°, ºÎ¹®º° ¿¹Ãø(2023-2030³â)

Nucleotide Market Size, Share & Trends Analysis Report By Product (Deoxy Nucleotides), By Technology (TaqMan Allelic Discrimination, Gene Chips & Microarrays), By Application, By Region, And Segment Forecasts, 2023 - 2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Grand View Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 120 Pages | ¹è¼Û¾È³» : 2-10ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óÇ°Àº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

´ºÅ¬·¹¿ÀƼµå ½ÃÀåÀÇ ¼ºÀå°ú µ¿Çâ :

Grand View Research, Inc.ÀÇ ÃֽŠ¸®Æ÷Æ®¿¡ µû¸£¸é ¼¼°èÀÇ ´ºÅ¬·¹¿ÀƼµå ½ÃÀå ±Ô¸ð´Â 2023-2030³â 7.12%ÀÇ CAGRÀ» ±â·ÏÇϸç, 2030³â¿¡´Â 13¾ï 7,725¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù.

¼¼°è ´ºÅ¬·¹¿ÀŸÀÌµå ½ÃÀåÀº Á¦¾à ¹× ½ÄÇ° ¹× À½·á »ê¾÷¿¡¼­ ±¤¹üÀ§ÇÏ°Ô »ç¿ëµÇ±â ¶§¹®¿¡ ¿¹Ãø ±â°£ Áß »ó´çÇÑ ¼ºÀåÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Áø´Ü ¿¬±¸ ¹× Á¦¾à ¿ëµµ´Â ¸é¿ª·Â °­È­, Àå °Ç°­ ¹× ½ºÆ®·¹½º ȸº¹¿¡ ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¡´Â Ư¼ºÀ¸·Î ÀÎÇØ ´ºÅ¬·¹¿ÀŸÀÌµå ½ÃÀåÀ» ÁÖµµÇÏ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ °¡Ãà ¿µ¾çÀ» À§ÇÑ È¿¸ð À¯·¡ ´ºÅ¬·¹¿ÀŸÀ̵å¿Í ÇÔ²² ½ÄÇ° ´ºÅ¬·¹¿ÀŸÀÌµå ºÐ¾ßÀÇ ¿¬±¸°³¹ßÀÌ ¼¼°è¿¡¼­ È®´ëµÇ°í ÀÖÀ¸¸ç, ÀÌ´Â ¿¹Ãø ±â°£ Áß ¼ö¿ä¸¦ ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

´ºÅ¬·¹¿ÀŸÀÌµå ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®

  • 2022³â ¼¼°è ½ÃÀåÀº TaqMan ´ë¸³À¯ÀüÀÚ ½Äº° ºÎ¹®ÀÌ Áö¹èÀûÀÏ °ÍÀ̸ç, ÆÄÀÌ·Î ½ÃÄö½ÌÀ» ÅëÇÑ SNP°¡ ±× µÚ¸¦ ÀÌÀ» °ÍÀÔ´Ï´Ù.
  • Áø´Ü ¿¬±¸ ºÎ¹®ÀÌ 2022³â ´ºÅ¬·¹¿ÀŸÀÌµå ¼¼°è ½ÃÀåÀ» Àå¾ÇÇÒ °ÍÀÔ´Ï´Ù.
  • µ¥¿Á½Ã´ºÅ¬·¹¿ÀƼµå(dNTPs) ºÎ¹®Àº 2022³â 47.49%ÀÇ ¸ÅÃâ Á¡À¯À²·Î ¼¼°è ´ºÅ¬·¹¿ÀƼµå ½ÃÀåÀ» Àå¾ÇÇÏ°í ¿¹Ãø ±â°£ Áß 7.34%ÀÇ °¡Àå ºü¸¥ CAGR·Î È®´ëµÉ °¡´É¼ºÀÌ ³ô½À´Ï´Ù.
  • ¾Æ½Ã¾ÆÅÂÆò¾çÀº ±âŸ Áö¿ª Áß °¡Àå ºü¸¥ ¼ºÀå¼¼¸¦ º¸À̸ç 2023-2030³â CAGR 7.81%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ Áö¿ª¿¡´Â ÁÖ¿ä ´ºÅ¬·¹¿ÀŸÀ̵å Á¦Á¶¾÷ü°¡ Á¸ÀçÇϸç, ¿µ¾ç º¸ÃæÁ¦ ¹× °Ç°­ ½ÄÇ° »ê¾÷ ¼ö¿ä Áõ°¡¿Í ÇÔ²² Á¦Ç° ¼ö¿ä°¡ Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ Æ¯È÷ ¾Æ½Ã¾ÆÅÂÆò¾ç¿¡¼­ ½ÄÇ° ¹× À½·á ÷°¡Á¦¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó ¿¹Ãø ±â°£ Áß ´ºÅ¬·¹¿ÀŸÀÌµå ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °¡´É¼ºÀÌ ³ô½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ´ºÅ¬·¹¿ÀƼµå ½ÃÀå º¯¼ö, µ¿Çâ, ¹üÀ§

  • ½ÃÀå °èÅë Àü¸Á
    • ¸ð½ÃÀå Àü¸Á
    • °ü·Ã/ºÎ¼ö ½ÃÀå Àü¸Á
  • º¸±Þ°ú ¼ºÀå Àü¸Á ¸ÅÇÎ
  • ½ÃÀå ¿ªÇÐ
    • ½ÃÀå ÃËÁø¿äÀÎ ºÐ¼®
    • ½ÃÀå ¾ïÁ¦¿äÀÎ ºÐ¼®
  • ´ºÅ¬·¹¿ÀƼµå ½ÃÀå ºÐ¼® Åø
    • ¾÷°è ºÐ¼® - Porter's Five Forces
    • PESTEL ºÐ¼®

Á¦4Àå ´ºÅ¬·¹¿ÀƼµå ½ÃÀå : Á¦Ç° ÃßÁ¤¡¤µ¿Ç⠺м®

  • ´ºÅ¬·¹¿ÀƼµå ½ÃÀå : ÁÖ¿ä Æ÷ÀÎÆ®
  • ´ºÅ¬·¹¿ÀƼµå ½ÃÀå : Á¦Ç° µ¿Çâ°ú ½ÃÀå Á¡À¯À² ºÐ¼®, 2022³â ¹× 2030³â
  • Deoxy Nucleotides
  • Dideoxynucleotides
  • rNTP(Nucleotides for RNA Synthesis)
  • Ç¥½Ä ´ºÅ¬·¹¿ÀƼµå

Á¦5Àå ´ºÅ¬·¹¿ÀƼµå ½ÃÀå : ±â¼ú ÃßÁ¤¡¤µ¿Ç⠺м®

  • ´ºÅ¬·¹¿ÀƼµå ½ÃÀå : ÁÖ¿ä Æ÷ÀÎÆ®
  • ´ºÅ¬·¹¿ÀƼµå ½ÃÀå : ±â¼ú µ¿Çâ°ú ½ÃÀå Á¡À¯À² ºÐ¼®, 2022³â ¹× 2030³â
  • TaqMan ´ë¸³ À¯ÀüÀÚ ½Äº°
  • À¯ÀüÀÚ Ä¨°ú ¸¶ÀÌÅ©·Î¾î·¹ÀÌ
  • ÆÄÀ̷νÃÄö½Ì¿¡ ÀÇÇÑ SNP
  • ±âŸ

Á¦6Àå ´ºÅ¬·¹¿ÀƼµå ½ÃÀå : ¾ÖÇø®ÄÉÀÌ¼Ç ÃßÁ¤¡¤µ¿Ç⠺м®

  • ´ºÅ¬·¹¿ÀƼµå ½ÃÀå : ÁÖ¿ä Æ÷ÀÎÆ®
  • ´ºÅ¬·¹¿ÀƼµå ½ÃÀå : ¾ÖÇø®ÄÉÀÌ¼Ç µ¿Çâ°ú ½ÃÀå Á¡À¯À² ºÐ¼®, 2022³â°ú 2030³â
  • ÀǾàÇ°
  • Áø´Ü Á¶»ç
  • ½ÄÇ° ¹× À½·á ÷°¡Á¦
  • µ¿¹° »ç·á÷°¡Á¦
  • ±âŸ

Á¦7Àå ´ºÅ¬·¹¿ÀƼµå ½ÃÀå : Áö¿ª ÃßÁ¤¡¤µ¿Ç⠺м®

  • Áö¿ªº° Àü¸Á
  • Áö¿ªº° ´ºÅ¬·¹¿ÀƼµå ½ÃÀå : ÁÖ¿ä Æ÷ÀÎÆ®
  • ºÏ¹Ì
    • ½ÃÀå Ã߻ꡤ¿¹Ãø, 2018-2030³â
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • ¿µ±¹
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • µ§¸¶Å©
    • ½º¿þµ§
    • ³ë¸£¿þÀÌ
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ÀϺ»
    • Áß±¹
    • Àεµ
    • È£ÁÖ
    • ű¹
    • Çѱ¹
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ¾Æ¸£ÇîƼ³ª
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®
    • Äí¿þÀÌÆ®

Á¦8Àå °æÀï ±¸µµ

  • ÁÖ¿ä ½ÃÀå Âü¿© ±â¾÷¿¡ ÀÇÇÑ ÃÖ±Ù µ¿Çâ°ú ¿µÇ⠺м®
  • ½ÃÀå Âü¿© ±â¾÷ÀÇ ºÐ·ù
    • CJ CHEILJEDANG CORP
    • Star Lake Bioscience Co., Inc.
    • Thermo Fisher Scientific Inc.
    • MEIHUA HOLDINGS GROUP CO., LTD.
    • F. Hoffmann-La Roche Ltd.
    • Biorigin
    • DSM Nutritional Products AG
    • Promega Corporation
    • Agilent Technologies Inc.
    • Lallemand Inc.
    • Nanjing Biotogether Co., Ltd.
    • NuEra Nutraceuticals Inc.
    • Ohly
KSA 23.11.15

Nucleotide Market Growth & Trends:

The global nucleotide market size is expected to reach USD 1,377.25 million by 2030, registering a CAGR of 7.12% from 2023 to 2030, according to a new report by Grand View Research, Inc.. The global nucleotide market is expected to witness substantial growth over the forecast period owing to its widespread use in pharmaceuticals and food & beverage industries. Diagnostic research along with pharmaceutical applications dominated the nucleotide market owning to properties including enhanced immunity, positive effects on the intestines, and positive effects of recovery from stress. In addition, growing R&D in the field of dietary nucleotide coupled with yeast-derived nucleotide for livestock nutrition across the globe is expected to propel demand over the forecast period.

Nucleotide Market Report Highlights:

  • The TaqMan allelic discrimination segment dominated the global market in 2022, followed by SNP by pyrosequencing
  • The diagnostics research segment dominated the global market for nucleotides in 2022
  • The deoxy nucleotides (dNTPs) segment dominated the global nucleotide market in 2022 with a revenue share of 47.49% and is furthermore likely to expand with the fastest CAGR of 7.34% over the forecast period
  • Asia Pacific is expected to witness the fastest growth among other regions, growing at a CAGR of 7.81% from 2023 to 2030. The presence of the leading nucleotide manufacturer in the region coupled with increasing demand for nutraceuticals and the health food industry is expected to increase demand for the product. In addition, increasing food & beverage additive explorations particularly Asia Pacific is likely to propel market growth for nucleotide over the forecast period

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Product
    • 1.1.2. Technology
    • 1.1.3. Application
    • 1.1.4. Regional scope
    • 1.1.5. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product outlook
    • 2.2.2. Technology outlook
    • 2.2.3. Application outlook
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Nucleotides Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Market Dynamics
    • 3.3.1. Market driver analysis
    • 3.3.2. Market restraint analysis
  • 3.4. Nucleotides Market Analysis Tools
    • 3.4.1. Industry Analysis - Porter's Five Forces
      • 3.4.1.1. Supplier power
      • 3.4.1.2. Buyer power
      • 3.4.1.3. Substitution threat
      • 3.4.1.4. Threat of new entrant
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Technological landscape
      • 3.4.2.3. Economic landscape

Chapter 4. Nucleotides Market: Product Estimates & Trend Analysis

  • 4.1. Nucleotides Market: Key Takeaways
  • 4.2. Nucleotides Market: Product Movement & Market Share Analysis, 2022 & 2030
  • 4.3. Deoxy Nucleotides
    • 4.3.1. Deoxy Nucleotides market estimates and forecasts, 2018 to 2030 (USD Million)
      • 4.3.1.1. By production method
      • 4.3.1.1.1. Enzyme sourced
      • 4.3.1.1.2. Chemical synthesis
  • 4.4. Dideoxynucleotides
    • 4.4.1. Dideoxynucleotides market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.5. Nucleotides for RNA Synthesis (rNTP)
    • 4.5.1. Nucleotides for RNA Synthesis (rNTP) market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.6. Labelled Nucleotides
    • 4.6.1. Labelled Nucleotides market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Nucleotides Market: Technology Estimates & Trend Analysis

  • 5.1. Nucleotides Market: Key Takeaways
  • 5.2. Nucleotides Market: Technology Movement & Market Share Analysis, 2022 & 2030
  • 5.3. TaqMan Allelic Discrimination
    • 5.3.1. TaqMan allelic discrimination market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4. Gene Chips & microarrays
    • 5.4.1. Gene chips & microarrays market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.5. SNP by Pyrosequencing
    • 5.5.1. SNP by pyrosequencing market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.6. Others
    • 5.6.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Nucleotides Market: Application Estimates & Trend Analysis

  • 6.1. Nucleotides Market: Key Takeaways
  • 6.2. Nucleotides Market: Application Movement & Market Share Analysis, 2022 & 2030
  • 6.3. Pharmaceuticals
    • 6.3.1. Pharmaceuticals market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.4. Diagnostics Research
    • 6.4.1. Diagnostics research market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.5. Food & Beverage Additive
    • 6.5.1. Food & beverage additive market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.6. Animal Feed Additive
    • 6.6.1. Animal feed additive market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.7. Others
    • 6.7.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 7. Nucleotides Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Outlook
  • 7.2. Nucleotides Market by Region: Key Takeaways
  • 7.3. North America
    • 7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.3.2. U.S.
      • 7.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.3.3. Canada
      • 7.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.4. Europe
    • 7.4.1. UK
      • 7.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.2. Germany
      • 7.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.3. France
      • 7.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.4. Italy
      • 7.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.5. Spain
      • 7.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.6. Denmark
      • 7.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.7. Sweden
      • 7.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.8. Norway
      • 7.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Japan
      • 7.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.5.2. China
      • 7.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.5.3. India
      • 7.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.5.4. Australia
      • 7.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.5.5. Thailand
      • 7.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.5.6. South Korea
      • 7.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.6. Latin America
    • 7.6.1. Brazil
      • 7.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.6.2. Mexico
      • 7.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.6.3. Argentina
      • 7.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.7. MEA
    • 7.7.1. South Africa
      • 7.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.7.2. Saudi Arabia
      • 7.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.7.3. UAE
      • 7.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.7.4. Kuwait
      • 7.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Market Participant Categorization
    • 8.2.1. CJ CHEILJEDANG CORP
      • 8.2.1.1. Company overview
      • 8.2.1.2. Financial performance
      • 8.2.1.3. Product benchmarking
      • 8.2.1.4. Strategic initiatives
    • 8.2.2. Star Lake Bioscience Co., Inc.
      • 8.2.2.1. Company overview
      • 8.2.2.2. Financial performance
      • 8.2.2.3. Product benchmarking
      • 8.2.2.4. Strategic initiatives
    • 8.2.3. Thermo Fisher Scientific Inc.
      • 8.2.3.1. Company overview
      • 8.2.3.2. Financial performance
      • 8.2.3.3. Product benchmarking
      • 8.2.3.4. Strategic initiatives
    • 8.2.4. MEIHUA HOLDINGS GROUP CO., LTD.
      • 8.2.4.1. Company overview
      • 8.2.4.2. Financial performance
      • 8.2.4.3. Product benchmarking
      • 8.2.4.4. Strategic initiatives
    • 8.2.5. F. Hoffmann-La Roche Ltd.
      • 8.2.5.1. Company overview
      • 8.2.5.2. Financial performance
      • 8.2.5.3. Product benchmarking
      • 8.2.5.4. Strategic initiatives
    • 8.2.6. Biorigin
      • 8.2.6.1. Company overview
      • 8.2.6.2. Financial performance
      • 8.2.6.3. Product benchmarking
      • 8.2.6.4. Strategic initiatives
    • 8.2.7. DSM Nutritional Products AG
      • 8.2.7.1. Company overview
      • 8.2.7.2. Financial performance
      • 8.2.7.3. Product benchmarking
      • 8.2.7.4. Strategic initiatives
    • 8.2.8. Promega Corporation
      • 8.2.8.1. Company overview
      • 8.2.8.2. Financial performance
      • 8.2.8.3. Product benchmarking
      • 8.2.8.4. Strategic initiatives
    • 8.2.9. Agilent Technologies Inc.
      • 8.2.9.1. Company overview
      • 8.2.9.2. Financial performance
      • 8.2.9.3. Product benchmarking
      • 8.2.9.4. Strategic initiatives
    • 8.2.10. Lallemand Inc.
      • 8.2.10.1. Company overview
      • 8.2.10.2. Financial performance
      • 8.2.10.3. Product benchmarking
      • 8.2.10.4. Strategic initiatives
    • 8.2.11. Nanjing Biotogether Co., Ltd.
      • 8.2.11.1. Company overview
      • 8.2.11.2. Financial performance
      • 8.2.11.3. Product benchmarking
      • 8.2.11.4. Strategic initiatives
    • 8.2.12. NuEra Nutraceuticals Inc.
      • 8.2.12.1. Company overview
      • 8.2.12.2. Financial performance
      • 8.2.12.3. Product benchmarking
      • 8.2.12.4. Strategic initiatives
    • 8.2.13. Ohly
      • 8.2.13.1. Company overview
      • 8.2.13.2. Financial performance
      • 8.2.13.3. Product benchmarking
      • 8.2.13.4. Strategic initiatives
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óÇ°À» ¼±Åà Áß
»óÇ° ºñ±³Çϱâ
Àüü»èÁ¦